Encorafenib /Binimetinib Showcases Sustained Responses in BRAF V600–Mutant Melanoma
Source: Oncology Nursing News, October 2022
A 5-year follow-up of the COLOMBUS trial showed that encorafenib plus binimetinib continued to provide clinical benefit for patients with melanoma harboring a BRAF V600 mutation.
BRAF/MEK inhibition with encorafenib (Braftovi) plus binimetinib (Mektovi) continued to provide long-term benefit, with a consistent safety profile, to patients with BRAF V600–mutant melanoma according to a 5-year follow-up of the pivotal COLUMBUS trial (NCT01909453).
Specifically, the regimen outperformed both single-agent vemurafenib (Zelboraf) and single-agent encorafenib in inducing long-term overall survival (OS) and progression-free survival (PFS) benefit. The PFS rates with the combination therapy was 23% in the all-randomized population (n = 192) and 31% in a cohort of patients with normal lactate dehydrogenase (LDH) levels (n = 137). The OS rates in these populations were 35% and 45%, respectively.